Palatin Technologies, Inc. has received $-0.08 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 2 Financial Advisor in the Stock Trading Firms. Among 2 Analysts, Bottom line EPS Estimate for the current quarter is $-0.08 while the top line estimate is $-0.08 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 0%.
Palatin Technologies, Inc. reported better than expected with a surprise EPS of 11.11% or $0.01 during its most recent quarterly earnings. The Actual EPS was $-0.08 compared to the Estimated EPS of $-0.09. Cranbury based Palatin Technologies, Inc. Last reported the Quarter results on Dec 31, 2016 and the Next earnings date is scheduled to be released on Feb 10, 2017.
In the last quarter, Palatin Technologies, Inc. reported Annual Earnings of $-0.08. Based on the filings, last years Annual Earnings was, $-0.33. In the last Quarter, PTN reported a surprise Earnings per Share of 11.11% . The consensus estimate for current quarter is $-0.08 and for the current fiscal year, the estimate is $-0.13. For the Next fiscal year, the estimate is $0.09 based on the consensus.
Palatin Technologies, Inc. (NYSEMKT:PTN) stock ended Tuesday session in the red zone in a volatile trading. The stock closed down 0.0055 points or 1.32% at $0.41 with 1,861,993 shares getting traded. Post opening the session at $0.4163, the shares hit an intraday low of $0.3878 and an intraday high of $0.4175 and the price was in this range throughout the day. The company has a market cap of $55 million and the number of outstanding shares has been calculated to be 133,423,837 shares. The 52-week high of Palatin Technologies, Inc. (NYSEMKT:PTN) is $0.8984 and the 52-week low is $0.3646.
Palatin Technologies, Inc is a development-stage medical technology company involved in developing and commercializing products and technologies for diagnostic imaging, cancer therapy and ethical drug development These developments are based on its proprietary monoclonal antibody radiolabeling and enabling peptide platform technologies.